Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way.

Eliyatkın N, Yalçın E, Zengel B, Aktaş S, Vardar E.

J Breast Health (2013). 2015 Apr 1;11(2):59-66. doi: 10.5152/tjbh.2015.1669. eCollection 2015 Apr 1. Review.

2.

Aberrant promoter methylation of cancer-related genes in human breast cancer.

Wu L, Shen Y, Peng X, Zhang S, Wang M, Xu G, Zheng X, Wang J, Lu C.

Oncol Lett. 2016 Dec;12(6):5145-5155. doi: 10.3892/ol.2016.5351. Epub 2016 Nov 4.

3.

Dual-Time 18F-FDG PET/CT Imaging in Initial Locoregional Staging of Breast Carcinoma: Comparison with Conventional Imaging and Pathological Prognostic Factors.

Ozen A, Altinay S, Ekmekcioglu O, Albayrak R, Muhammedoglu A, Yigitbas H, Bastug E, Celik A.

Indian J Surg. 2016 Oct;78(5):382-389. Epub 2016 Apr 23.

PMID:
27994334
4.

Comparisons of Oncologic Outcomes between Triple-Negative Breast Cancer (TNBC) and Non-TNBC among Patients Treated with Breast-Conserving Therapy.

Kim S, Park HS, Kim JY, Ryu J, Park S, Kim SI.

Yonsei Med J. 2016 Sep;57(5):1192-8. doi: 10.3349/ymj.2016.57.5.1192.

5.

Early breast cancer screening using iron/iron oxide-based nanoplatforms with sub-femtomolar limits of detection.

Udukala DN, Wang H, Wendel SO, Malalasekera AP, Samarakoon TN, Yapa AS, Abayaweera G, Basel MT, Maynez P, Ortega R, Toledo Y, Bossmann L, Robinson C, Janik KE, Koper OB, Li P, Motamedi M, Higgins DA, Gadbury G, Zhu G, Troyer DL, Bossmann SH.

Beilstein J Nanotechnol. 2016 Mar 7;7:364-73. doi: 10.3762/bjnano.7.33. eCollection 2016 Mar 7.

6.

The role and indications of aggressive locoregional therapy in metastatic inflammatory breast cancer.

Yan Y, Tang L, Tong W, Zhou J.

Sci Rep. 2016 May 13;6:25874. doi: 10.1038/srep25874.

7.

Polymorphisms of glutathione S-transferase π 1 and toll-like receptors 2 and 9: Association with breast cancer susceptibility.

Al-Harras MF, Houssen ME, Shaker ME, Farag K, Farouk O, Monir R, El-Mahdy R, Abo-Hashem EM.

Oncol Lett. 2016 Mar;11(3):2182-2188. Epub 2016 Jan 28.

8.

MicroRNA-30a increases tight junction protein expression to suppress the epithelial-mesenchymal transition and metastasis by targeting Slug in breast cancer.

Chang CW, Yu JC, Hsieh YH, Yao CC, Chao JI, Chen PM, Hsieh HY, Hsiung CN, Chu HW, Shen CY, Cheng CW.

Oncotarget. 2016 Mar 29;7(13):16462-78. doi: 10.18632/oncotarget.7656.

9.

Axillary ultrasound and fine-needle aspiration in preoperative staging of axillary lymph nodes in patients with invasive breast cancer.

Rocha RD, Girardi AR, Pinto RR, de Freitas VA.

Radiol Bras. 2015 Nov-Dec;48(6):345-52. doi: 10.1590/0100-3984.2014.0121.

10.

Latent class model characterization of neighborhood socioeconomic status.

Palumbo A, Michael Y, Hyslop T.

Cancer Causes Control. 2016 Mar;27(3):445-52. doi: 10.1007/s10552-015-0711-4. Epub 2016 Jan 21.

11.

Sentinel lymph nodes for breast carcinoma: an update on current practice.

Maguire A, Brogi E.

Histopathology. 2016 Jan;68(1):152-67. doi: 10.1111/his.12853. Review.

12.

Sentinel Lymph Node in Breast Cancer: Review Article from a Pathologist's Point of View.

Apple SK.

J Pathol Transl Med. 2016 Mar;50(2):83-95. doi: 10.4132/jptm.2015.11.23. Epub 2016 Jan 12. Review.

13.

Breast-conserving therapy and modified radical mastectomy for primary breast carcinoma: a matched comparative study.

Wang L, Ouyang T, Wang T, Xie Y, Fan Z, Lin B, Li J.

Chin J Cancer Res. 2015 Dec;27(6):545-52. doi: 10.3978/j.issn.1000-9604.2015.11.02.

14.

The Clinical Significance and Molecular Features of the Spatial Tumor Shapes in Breast Cancers.

Moon HG, Kim N, Jeong S, Lee M, Moon H, Kim J, Yoo TK, Lee HB, Kim J, Noh DY, Han W.

PLoS One. 2015 Dec 15;10(12):e0143811. doi: 10.1371/journal.pone.0143811. eCollection 2015 Dec 15.

15.

Male accessory breast cancer successfully treated with endocrine therapy: A case report.

Bi L, Li J, Shi Z, Zhu Z, Lu Z.

Oncol Lett. 2015 Oct;10(4):2495-2498. Epub 2015 Aug 12.

16.

Thrombin-activatable fibrinolysis inhibitor Thr325Ile polymorphism and plasma level in breast cancer: A pilot study.

Fawzy MS, Mohammed EA, Ahmed AS, Fakhr-Eldeen A.

Meta Gene. 2015 Apr 11;4:73-84. doi: 10.1016/j.mgene.2015.03.004. eCollection 2015 Apr 11.

17.

Luminal B subtype: a key factor for the worse prognosis of young breast cancer patients in China.

Tang LC, Jin X, Yang HY, He M, Chang H, Shao ZM, Di GH.

BMC Cancer. 2015 Mar 29;15:201. doi: 10.1186/s12885-015-1207-z.

18.
19.

Capecitabine-induced cardiotoxicity: more evidence or clinical approaches to protect the patients' heart?

Fontanella C, Aita M, Cinausero M, Aprile G, Baldin MG, Dusi V, Lestuzzi C, Fasola G, Puglisi F.

Onco Targets Ther. 2014 Sep 29;7:1783-91. doi: 10.2147/OTT.S65653. eCollection 2014 Sep 29.

20.

miRNA as potential biomarkers of breast cancer in the Lebanese population and in young women: a pilot study.

Nassar FJ, El Sabban M, Zgheib NK, Tfayli A, Boulos F, Jabbour M, El Saghir NS, Talhouk R, Bazarbachi A, Calin GA, Nasr R.

PLoS One. 2014 Sep 18;9(9):e107566. doi: 10.1371/journal.pone.0107566. eCollection 2014 Sep 18.

Supplemental Content

Support Center